Press Releases

KKR to Invest in Arbor Pharmaceuticals

December 4, 2014

KKR to Invest in Arbor Pharmaceuticals Significant Minority Stake To Help Drive Continued Growth Atlanta, GA and New York, NY Gndash; December 4, 2014 – Arbor Pharmaceuticals (“Arbor”), a specialty pharmaceutical company, today announced that KKR, a leading global investment firm, is acquiring a significant minority stake in the company. Financial terms of the transaction…

Read More

Arbor Pharmaceuticals Announces FDA Approval of Sotylize™

October 23, 2014

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Sotylize (sotalol hydrochloride) oral solution. Sotylize is the first and only sotalol oral solution indicated for the treatment of documented life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with…

Read More

Arbor Pharmaceuticals Announces FDA Acceptance for Filing of its Second NDA

March 19, 2014

Atlanta, GA – Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its second New Drug Application (NDA). The NDA was originally filed with the FDA on December 23, 2013 and officially accepted for filing on February 23, 2014. Arbor’s first NDA, Nymalize® (nimodipine) oral solution, was approved in…

Read More

Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR

September 12, 2013

Takeda and Arbor enter into a license, development and commercialization agreement for EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Deerfield, Ill., Osaka, Japan, and Atlanta, September 12, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC (“Arbor”) announced today that Takeda…

Read More

Arbor Pharmaceuticals Announces FDA Approval of First NDA

May 13, 2013

Atlanta, GA — Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Nymalize™ (nimodipine) oral solution. Nymalize was previously granted Orphan designation which provides seven years of market exclusivity. Nymalize is the first and only nimodipine oral solution indicated for the improvement of neurological outcome…

Read More

Eisai Inc. Divests U.S. Rights for GLIADEL® Wafer (polifeprosan 20 with carmustine implant) to Arbor Pharmaceuticals

December 17, 2012

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset purchase agreement to divest U.S. rights for Gliadel® Wafer (polifeprosan 20 with carmustine implant) to specialty pharmaceutical company Arbor Pharmaceuticals, Inc.

Read More